Bio-Techne Co. (NASDAQ:TECH - Free Report) - Equities research analysts at William Blair reduced their Q4 2025 earnings estimates for shares of Bio-Techne in a research report issued on Wednesday, February 5th. William Blair analyst M. Larew now forecasts that the biotechnology company will earn $0.51 per share for the quarter, down from their prior forecast of $0.52. The consensus estimate for Bio-Techne's current full-year earnings is $1.68 per share. William Blair also issued estimates for Bio-Techne's Q1 2026 earnings at $0.44 EPS, Q2 2026 earnings at $0.45 EPS, Q3 2026 earnings at $0.56 EPS and Q4 2026 earnings at $0.61 EPS.
Bio-Techne (NASDAQ:TECH - Get Free Report) last released its earnings results on Wednesday, February 5th. The biotechnology company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.03). Bio-Techne had a net margin of 13.22% and a return on equity of 12.73%.
A number of other equities analysts have also recently issued reports on TECH. Royal Bank of Canada upped their target price on Bio-Techne from $79.00 to $80.00 and gave the stock a "sector perform" rating in a report on Thursday, February 6th. Robert W. Baird raised their price target on shares of Bio-Techne from $82.00 to $84.00 and gave the company an "outperform" rating in a research note on Thursday, October 31st. Scotiabank lifted their target price on Bio-Techne from $88.00 to $90.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 6th. StockNews.com upgraded Bio-Techne from a "hold" rating to a "buy" rating in a research report on Tuesday, November 12th. Finally, KeyCorp upped their target price on Bio-Techne from $80.00 to $90.00 and gave the company an "overweight" rating in a report on Thursday, February 6th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $86.57.
Check Out Our Latest Stock Report on TECH
Bio-Techne Price Performance
Shares of TECH stock traded down $0.67 on Monday, reaching $66.77. The company had a trading volume of 1,766,103 shares, compared to its average volume of 1,289,279. Bio-Techne has a one year low of $61.16 and a one year high of $85.57. The company has a quick ratio of 3.26, a current ratio of 3.94 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $10.61 billion, a PE ratio of 67.44, a price-to-earnings-growth ratio of 5.54 and a beta of 1.27. The business's 50-day moving average is $74.14 and its 200 day moving average is $74.11.
Hedge Funds Weigh In On Bio-Techne
Several hedge funds have recently modified their holdings of the company. Norges Bank bought a new stake in Bio-Techne in the fourth quarter worth about $137,301,000. Point72 Asset Management L.P. purchased a new position in shares of Bio-Techne in the third quarter valued at $89,724,000. Raymond James Financial Inc. bought a new stake in shares of Bio-Techne during the 4th quarter valued at $44,479,000. Invesco Ltd. lifted its holdings in Bio-Techne by 10.4% during the 4th quarter. Invesco Ltd. now owns 3,820,464 shares of the biotechnology company's stock worth $275,188,000 after purchasing an additional 358,756 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. boosted its stake in Bio-Techne by 21.0% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,040,840 shares of the biotechnology company's stock worth $147,002,000 after purchasing an additional 354,478 shares during the period. Institutional investors own 98.95% of the company's stock.
Insider Buying and Selling at Bio-Techne
In other news, CEO Kim Kelderman sold 13,392 shares of the company's stock in a transaction on Monday, January 27th. The shares were sold at an average price of $77.29, for a total value of $1,035,067.68. Following the completion of the sale, the chief executive officer now owns 39,004 shares in the company, valued at $3,014,619.16. This represents a 25.56 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 3.90% of the stock is currently owned by company insiders.
Bio-Techne Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, February 28th. Shareholders of record on Monday, February 17th will be issued a $0.08 dividend. The ex-dividend date is Friday, February 14th. This represents a $0.32 annualized dividend and a yield of 0.48%. Bio-Techne's payout ratio is currently 32.32%.
About Bio-Techne
(
Get Free Report)
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.
See Also
Before you consider Bio-Techne, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Techne wasn't on the list.
While Bio-Techne currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
